CompARE:比较中危及高危口咽癌升级治疗替代方案的III期随机对照平台试验研究方案
CompARE是一项实用性III期、开放标签、多中心随机对照试验,采用适应性多臂多阶段设计并整合QuinteT招募干预,旨在检验中危及高危口咽癌的强化治疗替代方案以改善生存。原设计四臂中三个实验臂已停止招募,新增第5臂为诱导度伐利尤单抗后标准治疗再辅助度伐利尤单抗。主要终点为总生存时间,中期主要终点为无事件生存时间。
要点
- CompARE针对中危及高危口咽癌患者,比较强化治疗替代方案与标准治疗。
- 目前招募第1臂(对照:顺铂联合调强放疗)和第5臂(诱导度伐利尤单抗后标准治疗再辅助度伐利尤单抗)。
- 主要终点为总生存时间,中期主要终点为无事件生存时间。
核心结论
- CompARE旨在高效、经济地应对新数据、新治疗或困难,目标是为中危及高危口咽癌患者带来新的治疗选择。
研究设计与样本
- CompARE是一项实用性III期、开放标签、多中心随机对照试验,采用适应性多臂多阶段设计并整合QuinteT招募干预。
- 合格口咽癌患者包括人乳头瘤病毒(HPV)阴性、T1-T4、N1-N3或T3-4、N0,或HPV阳性N3、T4,或当前吸烟者(或既往吸烟史≥10包年)伴T1-T4、N2b-N3。
- 原设计四臂:第1臂对照,第2臂诱导化疗后接第1臂,第3臂剂量递增放疗联合同步顺铂,第4臂原发灶切除后接第1臂;三个原实验臂已停止招募,新增第5臂诱导度伐利尤单抗后接第1臂再辅助度伐利尤单抗。
- 目前招募第1臂(对照):每3周顺铂100 mg/m2或每周40 mg/m2联合调强放疗70 Gy分35次,治疗后3个月根据临床和影像学评估决定是否颈部清扫;第5臂(干预):一周期诱导度伐利尤单抗1500 mg后标准治疗,再度伐利尤单抗1500 mg每4周共6个月。
- 设计预计约7年后发生84个所需事件,以分析该对比的确定性主要终点;计划使用无事件生存时间进行中期无效性分析。
主要发现
- 中危及高危口咽癌患者相比低危口咽癌患者对标准治疗反应更差且总生存更差。
- 主要终点为总生存时间,中期主要终点为无事件生存时间。
- 次要终点包括生活质量、毒性、吞咽结局、喂养管发生率、手术并发症发生率和成本效果。
关键数值与推荐
- 第1臂标准治疗为每3周顺铂100 mg/m2或每周40 mg/m2联合调强放疗70 Gy分35次,治疗后3个月根据临床和影像学评估决定是否颈部清扫。
- 第5臂干预为一周期诱导度伐利尤单抗1500 mg后标准治疗,再度伐利尤单抗1500 mg每4周共6个月。
- 设计预计约7年后发生84个所需事件以分析确定性主要终点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with intermediate and high-risk oropharyngeal cancer (OPC) have poorer response to standard treatment and poorer overall survival compared to low-risk OPC. CompARE is designed to test alternative approaches to intensified treatment for these patients to improve survival. METHODS: CompARE is a pragmatic phase III, open-label, multicenter randomised controlled trial with an adaptive multi-arm, multi-stage design and an integrated QuinteT Recruitment Intervention. Eligible OPC patients include those with human papillomavirus (HPV) negative, T1-T4, N1-N3 or T3-4, N0, or HPV positive N3, T4, or current smokers (or ≥ 10 pack years previous smoking history) with T1-T4, N2b-N3. CompARE was originally designed with four arms (one control [arm 1] and three experimental: arm 2-induction chemotherapy followed by arm 1; arm 3-dose-escalated radiotherapy plus concomitant cisplatin; and arm 4-resection of primary followed by arm 1). The three original experimental arms have been closed to recruitment and a further experimental arm opened (arm 5-induction durvalumab followed by arm 1 and then adjuvant durvalumab). Currently recruiting are arm 1 (control): standard treatment of 3-weekly cisplatin 100 mg/m2 or weekly 40 mg/m2 with intensity-modulated radiotherapy using 70 Gy in 35 fractions ± neck dissection determined by clinical and radiological assessment 3 months post-treatment, and arm 5 (intervention): one cycle of induction durvalumab 1500 mg followed by standard treatment then durvalumab 1500 mg every 4 weeks for a total of 6 months. The definitive and interim primary outcome measures are overall survival time and event-free survival (EFS) time, respectively. Secondary outcome measures include quality of life, toxicity, swallowing outcomes, feeding tube incidence, surgical complication rates, and cost-effectiveness. The design anticipates that after approximately 7 years, 84 required events will have occurred to enable analysis of the definitive primary outcome measure for this comparison. Planned interim futility analyses using EFS will also be performed. DISCUSSION: CompARE is designed to be efficient and cost-effective in response to new data, emerging new treatments or difficulties, with the aim of bringing new treatment options for these patients. TRIAL REGISTRATION: ISRCTN ISRCTN41478539 . Registered on 29 April 2015.
引用
- Mehanna H, Gaunt P, Kong A, et al. CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer. Trials. 2024. PMID: 38221636. doi:10.1186/s13063-023-07881-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。